Curevac receives additional positive validity decision from european patent office in ongoing litigation against biontech se

European patent office largely dismisses opposition filed by biontech se, pfizer inc., and others in december 2023 challenging validity of ep 4 023 755 b1 and maintains the patent subject to amendments to specific patent claims a hearing on infringement of ep 4 023 755 b1 which will also include ep 3 708 668 b1, the validity of which was confirmed in amended form in march 2025, is scheduled for july 1, 2025, before the regional court dÜsseldorf, germany tubingen, germany and boston, ma / access newswire / may 15, 2025 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that the european patent office (epo) has confirmed the validity of curevac's european patent ep 4 023 755 b1 subject to amendments to specify the scope of protection.
CVAC Ratings Summary
CVAC Quant Ranking